Dr. Parsons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-1992Fax+1 617-632-1930
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- Johns Hopkins UniversityResidency, Internal Medicine, 2009 - 2012
Drexel University College of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2015 - 2026
MD State Medical License 2013 - 2015- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Start of enrollment: 2017 Oct 25
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 138 citationsAssociation of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Daniel G. Stover, Heather A. Parsons, Gavin Ha, Samuel S. Freeman, William T. Barry
Journal of Clinical Oncology. 2018-01-03 - 3 citations'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.Rachel A Freedman, Tianyu Li, Mina S Sedrak, Judith O Hopkins, Nabihah Tayob
Journal of Geriatric Oncology. 2023-01-01 - 4 citationsCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos
Medrxiv. 2023-03-08
Journal Articles
- Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate CancerHeather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation
Press Mentions
Evolving Conversations in HER2+ Oligometastatic Breast Cancer ManagementSeptember 19th, 2024- STOP-HER2: Stopping Trastuzumab in HER2+ MBCFebruary 9th, 2023
- Tumor DNA Assay Portends Metastatic Breast Cancer Recurrence Months in AdvanceJune 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
